The Next Big Niche? Emerging Med-Tech for Transplant. MedCity News Molecular diagnostics companies such as XDx are developing tests for non-invasively detecting early signs of transplant rejection, and predictive biomarkers for rejection predisposition are being pursued for personalized immunosuppressive therapy. On ... |
